Michael Bloch, MD, on Hypercholesterolemia: A Focus on PCSK9 Inhibitors
11/19/2019
In this video, Michael Bloch, MD, talks about his session at the Cardiometabolic Risk Summit 2019, which reviewed the latest clinical data for PCSK9 inhibitors in lowering LDL-C and cardiovascular events, assessed current evidence for the optimum LDL-C goals for patients with hypercholesterolemia, and more.
